Nasal spray may offer room temperature distribution that could reduce logistical  challenges for healthcare systems and providers Intranasal administration targets the virus at its point of entry and in a preclinical study induced local nasal mucosal immunity believed to be critical for preventing

Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced Development of AdCOVID Vectors Targeting Emerging Variants  of the SARS-CoV-2 Virus has Begun ALT-801 is Progressing Through the Phase 1 Clinical Trial Solidly Capitalized to Advance Pipeline Candidates with $216 Million in  Cash and

GAITHERSBURG, Md. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25 th , 2021. Altimmune management will host a conference call for

Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week GAITHERSBURG, Md. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S.